Payors Weigh in on Interface of Personalized Medicine and Comparative Effectiveness Research

While payors speaking at a recent conference seemed to be of the opinion that personalized medicine lacks the evidentiary support to justify broad coverage, they suggested that CER may be a way to gather the necessary data on whether to reimburse for genomically guided medicines.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.